期刊文献+

人乳头瘤病毒6型L1蛋白在原核表达体系中的表达 被引量:1

Expression of recombinant HPV6 L1 protein in prokaryotic expressing system
下载PDF
导出
摘要 目的:比较人乳头瘤病毒6型(HPV6)L1序列的变异,并筛选有代表性的分离标本进行重组HPV6L1蛋白的表达和抗原性检测。方法:根据不同临床特征选择主要致病型HPV6型8个分离标本,扩增L1基因,构建重组测序质粒。分析L1区的氨基酸序列变异状况,选择L1序列变异较大的临床分离标本,通过对HPV6L1基因的起始和终止端进行基因定点改造,连于表达载体质粒pET32a,在原核表达体系表达重组HPV6L1蛋白,并进行L1蛋白的抗原性检测。结果:HPV6型8个分离标本中有6个分离标本L1区的蛋白质一级结构中分别有1~3个氨基酸发生变异,原核表达重组L1蛋白可与HPV6L1抗体发生特异反应。说明HPV6L1序列的变异并未影响L1蛋白的抗原性。结论:本临床分离标本可提供发展HPV6L1蛋白和病毒样颗粒(VLP)疫苗的候选目的基因,并可通过原核表达体系表达重组HPVL1蛋白进行L1蛋白的免疫学分析,以及L1蛋白疫苗的研究。 Objective:To investigate the intratype sequence variation of HPV6L1ORF,the expression of recombinant L1protein from typical HPV6isolate and the detection of their antigenicity.Methods:Eight isolates of HPV6with different clinical manifestation were chosen.L1genes were amplified and inserted into sequencing plasmid.Intratype amino acid se-quence variation was assessed.After site-directed mutagenesis of some rare codons near the L1start and final sequence,a typical variation of HPV6L1ORF was cloned into the plasmid pET32a.Results:HPV6L1capsid protein was expressed within prokaryotic system.The antigenicity of the recombinant L1protein was tested.Results revealed there was1to3amino acids changed in different L1sequences in six isolates respectively.Recombinant L1capsid protein was expressed and com-bined with HPV6L1antibody.Conclusions:L1intratype amino sequence variation didn't affect L1protein antigenicity.The isolate could be selected as a target gene for recombinant HPV6L1virus-like particles (VLP).Prokaryotic expression system could be used to express recombinant HPV6L1protein for immunogenicity analysis and vaccine development.
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2003年第6期311-314,共4页 Journal of Clinical Dermatology
关键词 尖锐湿疣 人乳头瘤病毒 型内变异 原核表达 抗原性 疫苗 condyloma acuminatum human papillomavirus intratype variation prokaryotic expression antigenicity vaccine
  • 相关文献

参考文献1

二级参考文献11

  • 1[10]Icenogle J P,Sathya P,Rawls W E,et al.Nucleotide and amino acid sequence variations in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16[J].Virology,1991,184:101-107.
  • 2[11]Saiki R K,Gelfand D H,Erlich H A,et al.Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase[J].Science,1988,239:487-491.
  • 3[1]Zhou J,Sun X Y,Frazer I H,et al.Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles[J].Virology,1991,185:251-257.
  • 4[2]Bauer H M,Ting Y,Manos M M,et al.Genital Human Papillomavirus Infection in Female University Students as Determined by a PCR-Based Method[J].JAMA,1991,265(4):472-477.
  • 5[3]Bernard H U,Chan S Y,Wheeler C M,et al.Identification and Assessment of Known and Novel Human Papillomaviruses by PCR Amplification,Restriction Fragment Length Polymorphism, Nucleotide Sequence and Phylogenetic Algorithms[J].J Infect Dis,1994,170:1077-1085.
  • 6[4]Ethel-Michele de Villiers.Papillomavirus and HPV typing[J].Clin Dermatol,1997,15:199-206.
  • 7[5]Touze A, Mehaodui SEL,Sizaret P Y,et al.The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system[J].J Clin Microbiol,1998,36:2046-2051.
  • 8[6]Hofmann K J,Cook J C,Jansen K U,et al.Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in saccharomyces cerevisiae[J].Virology,1995,209:506-518.
  • 9[7]Wanderley W C,Savage N,Davies D H,et al.Intratypic sequence variation among clinical isolates of the human papillomavirus type 6 L1 ORF:Clustering of mutations and identification of a frequent amino acid sequence variant[J].J Gen Virol,1999,80:1025-1033.
  • 10[8]Suzuki T,Tshimi Y,Simizu B,et al.Deletion in the L1 open reading frame of human papillomavirus type 6a genomes associated with recurrent laryngeal papilloma[J].J Med Virol,1995,47:191-197.

共引文献6

同被引文献7

  • 1Arvin AM. Varicella-zoster virus[A]. In: Fields BN, Knipe DM,Howley PM. Fields Virology[M]. 3rd edition. Philadelphia:Lippincott-Raven, 1996. 2547-2548. 145-146.
  • 2Hasan UA, Abai AM, Harper DR, et al. Nucleic acid immunization: concepts and techniques associated with third generation vaccines[J]. J Immunol Methods, 1999, 229(1-2): 1-22.
  • 3Roitt IM, Delves PJ. Encyclopedia of Immunology[M]. Great Britain: Academic Press, 1992. 1548-1549.
  • 4Arvin AM, Mallory S, Moffat JF. Development of recombinant varicella-zoster virus vaccines[J]. Contrib Microbiol, 1999, 3:193-200.
  • 5Stasikova J, Kutinova L, Smahel M, et al. Immunization with Varicella-zoster virus glycoprotein E expressing vectors: Comparison of antibody response to DNA vaccine and recombinant vaccinia virus[J]. Acta Virol, 2003,47(1): 1-10.
  • 6Caleo M, Menna E, Chierzi S, et al. Brain-derived neurotrophic factor is an anterograde survival factor in the rat visual system [J]. Curr Biol, 2000, 10(19): 1155-1161.
  • 7Haumont M, Jurdan M, Kangro H, et al. Neutralizing antibody responses induced by varicella-zoster virus gE and gb glycoproteins following infection, reactivation or immunization[J]. J Med Virol, 1997, 53(1): 63-68.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部